Microbot Medical Inc.
Dr. Giora Weisz, a Training Interventional Cardiologist and Medical Researcher who was One of the Early Customers of Robotic-Enhanced Coronary Interventions, in addition to Navigation and Positioning Applied sciences, Would be the Visitor Speaker.
The Webinar is Meant for All Stakeholders within the Future of Endovascular Robotics, and Shall be Held on Wednesday, February 8, 2023, at 1:00pm ET
HINGHAM, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the primary single-use endovascular robotic system, introduced the subsequent episode of its extremely profitable “Access-Ability Live by MBOT” webinar, which is meant for all stakeholders within the endovascular robotic house and can be held on Wednesday, February 8, 2023, at 1:00pm ET. Will probably be hosted by the Firm’s Chief Medical Officer, Dr. Eyal Morag.
Dr. Morag’s visitor speaker can be Dr. Giora Weisz, an interventional heart specialist and Affiliate Professor of Drugs at Columbia College Medical Middle, Director of Interventional Cardiology on the New York-Presbyterian Hudson Valley Hospital, and a member of the school of the Middle of Interventional Vascular Remedy at Columbia College Medical Middle. He’s additionally a school member on the Cardiovascular Analysis Basis in New York. Dr. Weisz, who has a specific curiosity in present and progressive applied sciences in cardiovascular medication, is an early adopter of robotic-enhanced coronary interventions, in addition to navigation and positioning applied sciences. Dr. Weisz, who carried out Corindus Vascular Robotics’ (acquired by Siemens Healthineers) First-in-Human (FIH) medical trial to consider the protection and technical efficacy of Corindus’ CorePath system in delivering and manipulating coronary guidewires and stent/balloon methods in PCI procedures and was the primary to use this method on sufferers within the U.S., will share his private experiences utilizing a quantity of totally different endovascular robotic methods whereas addressing the present and future landscapes for endovascular procedures and the vital function of surgical robotics to handle future medical wants.
Story continues
The “Access-Ability Live by MBOT” webinar sequence focuses on key matters within the healthcare and endovascular house. Every month, the Firm can be partnering with trade leaders, equivalent to physicians, hospital directors, entrepreneurs, technicians and monetary consultants for a reside dialogue and Q&A session to handle top-of-mind matters associated to endovascular procedures.
You’ll be able to register for the upcoming webinar right here:
https://us06web.zoom.us/webinar/register/WN_iYewlRGNQDaXwE9H2cG28Q
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical gadget firm that focuses on transformational micro-robotic applied sciences, centered totally on each pure and synthetic lumens throughout the human physique. Microbot’s present proprietary technological platforms present the inspiration for the event of a Multi Technology Pipeline Portfolio (MGPP).
Microbot Medical was based in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the targets of bettering medical outcomes for sufferers and rising accessibility by way of the use of micro-robotic applied sciences. Additional details about Microbot Medical is obtainable at http://www.microbotmedical.com.
Secure Harbor
Statements made on this press launch or by members of Microbot’s administration group and others on Entry-Potential Live, relating to future monetary and/or working outcomes, future development in analysis, expertise, medical growth, and potential alternatives for Microbot Medical Inc. and its subsidiaries, together with different statements in regards to the future expectations, beliefs, targets, plans, or prospects expressed by administration, represent forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995 and the Federal securities legal guidelines. Any statements that aren’t historic reality (together with, however not restricted to statements that include phrases equivalent to “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) must also be thought of to be forward-looking statements. Ahead-looking statements contain dangers and uncertainties, together with, with out limitation, market circumstances, dangers inherent within the growth and/or commercialization of potential merchandise, together with LIBERTY and the One & Accomplished™ applied sciences, the result of its research to consider LIBERTY, the One & Accomplished™ applied sciences and different current and future applied sciences, any failure or incapability to recruit physicians and clinicians to function major investigators to conduct regulatory research, which may adversely have an effect on or delay such research, uncertainty within the outcomes of pre-clinical and medical trials or regulatory pathways and regulatory approvals, uncertainty ensuing from the COVID-19 pandemic, want and skill to acquire future capital, and upkeep of mental property rights. Extra info on dangers going through Microbot Medical may be discovered underneath the heading “Risk Factors” in Microbot Medical’s periodic stories filed with the Securities and Trade Fee (SEC), which can be found on the SEC’s web page at www.sec.gov. Microbot Medical disclaims any intent or obligation to replace these forward-looking statements, besides as required by legislation.
Statements, views and opinions expressed by friends of the Entry-Potential Live by MBOT webcast sequence are theirs solely, and don’t essentially mirror the statements, views and opinions of their employers, organizations and/or associations, or of Microbot Medical Inc. and its subsidiaries. Sure friends of Entry-Potential are members of the Scientific Advisory Board (SAB) of Microbot or paid consultants of Microbot, and have obtained compensation for his or her providers to Microbot.
Investor Contact:
Michael Polyviou
EVC Group
mpolyviou@evcgroup.com | 732-933-2754
0 Comments